|drug2301||Olokizumab 64 mg Wiki||0.71|
|drug3219||Standard treatment Wiki||0.38|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
This study is a multi-center randomized, controlled, and blinded clinical trial study that will be performed in four medical-educational centers. In this study, the samples will be selected from among patients with SARS-CoV-2 as easy access and based on entry criteria and will be randomly divided into two groups, including a control group and an intervention group. The study will be conducted in four medical centers. From each center, 56 definitive Corona patients will be selected, who will be randomly divided into two groups of 28, for a total of 224 patients will enter the study. In the intervention group, in addition to receiving the test spray, Patients will also receive standard treatment
Description: shortness of breath measured by Visual analog scale (VAS) dyspnea score. The minimum score is zero means shortness of breath and the highest score is 10 means the maximum intensity of shortness of breath.Measure: Dyspnea Time: up to 14 days
Description: The length of time the patient is hospitalized after the diagnosis of COVID-19Measure: long of hospitalization Time: up to 28 days
Description: CT scans help determine how much the lungs are affected by COVID-19.Measure: Radiological Treatment Response Time: up to 14 days
Description: In-hospital mortalityMeasure: Mortality Time: Up to 28 days
Description: There will be known allergic reactions to the drugs.Measure: Allergic drug Time: up to 14 days
Description: Normal blood cell count and CRP count (normal laboratory range)Measure: Laboratory Treatment Response Time: up to 14 days
Description: Using an oximeter pulse, the amount of oxygen saturation is measured. If the patient is receiving oxygen, first cut off the oxygen for 5 minutes and then measure. If the oxygen drops below 90 degrees, oxygen therapy will be re-established immediately.Measure: O2 saturation without supplemental oxygen Time: up to 14 days
Description: Complications in both groups should be evaluated and evaluated during treatment. protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions that measured by Physical examination.Measure: drug reactions Adverse Time: Up to 14 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports